Fully agree. As further proof that Anavex is preparing for commercialization, Just look at how they've restructured their chain of command by hiring Dr. Kun Jin as Vice President Head of Biostatistics....and promoting Dr. Jiong Ma to Chairman of the Board. (See below)
Anavex Life Sciences Appoints Former FDA Lead Neurology Statistician as VP Head of Biostatistics
I agree with you about the AD OLE comment indicating his positive outlook on AD approval. As for commercialization, that can be justified by optimism about Rett by itself, especially as Missling's plans for Rett will require a lot more commercial activity than his Alzheimer's plans.